FDA approves Nucletron brachytherapy treatment planning solution

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has cleared Nucletron’s Oncentra Brachy, a new comprehensive volume-based treatment planning solution to optimize cancer treatment planning with brachytherapy.

Oncentra Brachy, a fully DICOM-compatible treatment planning system, features optimization algorithms to shorten time spent planning, the Veenendaal, Netherlands-based Nucletron said.

Among the many features, the company said its new solution provides 3D contouring and margining tools to identify regions of interests on CT or in multimodality imaging environments using image registration for CT, MR and PET data.